Core Viewpoint - The company is establishing a Co-Chief Executive Officer (Co-CEO) system to enhance its global strategy and operational efficiency, with Dr. Andrea Wang-Gillam appointed as Co-CEO effective November 12, 2025 [1] Group 1: Leadership Changes - Dr. Andrea Wang-Gillam, currently the Chief Medical Officer, will transition to the role of Co-CEO [1] - Dr. Wang-Gillam has over 20 years of experience as an oncologist in the U.S. and is recognized as an expert in gastrointestinal oncology [1] Group 2: Strategic Implications - The establishment of the Co-CEO role is a significant step in the company's global strategy, aiming to create a collaborative model of "global strategic coordination + regional deep cultivation" [1] - This strategic adjustment is expected to generate greater value for the company's shareholders [1]
加科思-B委任王宜为联席首席执行官